1 and February, 2022 1 1, CAStem cell injection (acceptance number cxsl21kloc-0/443) developed by Hui Ze Biotech was officially approved by the Drug Evaluation Center of the State Pharmaceutical Products Administration, and phase II clinical trials of CAStem cell injection in the treatment of acute respiratory distress syndrome were carried out.
2. On February 8, 2022, two new applications for clinical trial registration (IND) of human umbilical cord mesenchymal stem cell injection independently developed by Shanghai Aisaer Biotechnology Co., Ltd. were accepted by the Drug Evaluation Center (CDE) of the State Administration of Pharmaceutical Products.
3. The application for clinical trial of a new T-MSC stem cell drug (IMS00 1 injection) independently developed by Zhuhai Hengqin Amstein Biotechnology Co., Ltd. was officially accepted by the Drug Evaluation Center (CDE) of China State Pharmaceutical Product Supervision and Administration.
4. On February 5th, 2022, CG-BM 1 allogeneic human bone marrow mesenchymal stem cell injection (acceptance number CXSL2 10 1334) independently developed by Guangzhou Saijuan Biotechnology Co., Ltd. was officially approved by the Drug Evaluation Center of the State Medical and Drug Administration for drug clinical trials.
5.2021118, the clinical trial of treating idiopathic pulmonary fibrosis (IPF) with umbilical cord mesenchymal stem cell injection was registered by Frye Medical Applicant, and it was approved by CDE, Drug Evaluation Center of State Pharmaceutical Products Administration.
6.202 1,1,Jiangsu Kangde Bio, a subsidiary of Kefeiping Medicine, independently developed a new kind of drug-allogeneic human adipose-derived mesenchymal stem cell injection (R&D code DK-00 1), and obtained the implied permission of clinical trials. Indications are complex perianal fistula in adult patients with inactive/mildly active intracavitary Crohn's disease.
In September, 20021year, the injection of human umbilical cord mesenchymal stem cells declared by Bosheng Zhuo Yue Biotechnology (Beijing) Co., Ltd. was used to treat acute graft-versus-host disease, which was ineffective in hormone therapy. As a kind of therapeutic biological products, it has obtained the implied permission of clinical trials from the Drug Evaluation Center (CDE) of the State Pharmaceutical Products Administration (acceptance number: CXSB2 10 1025).